On August 24, INNOVENT BIO fell 3.13% in regular trading, trading at HK$99.35/share, with turnover of HK$342 million.

On the news front, the company is scheduled to hold a board meeting on August 25 to review its interim results, and the market is showing signs of profit-taking ahead of the earnings release. The broader biotech sector weakened in tandem, with BeiGene down 3.42%, CanSinoBio down 4.95%, and Akeso down 1.05%. Meanwhile, southbound capital has cumulatively net sold over 13.18 million shares of the company over the past 20 trading days, and innovative drug ETF shares have seen notable shrinkage, indicating short-term funding pressure.

Earlier this month, the company disclosed first-half product revenue exceeding RMB 8.2 billion, up over 55% year-over-year, with Q2 revenue surpassing RMB 4.3 billion, up approximately 60%. Morgan Stanley recently raised its target price to HK$138.5, while BlackRock increased its stake to 5.01% on August 12.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)